Cancer Profiling Market Report 2026

The cancer profiling market size has grown rapidly in recent years. It will grow from $15 billion in 2025 to $16.67 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increasing cancer incidence rates, expansion of molecular diagnostics laboratories, early adoption of genomic testing in oncology, growth in research-based cancer profiling, rising availability of diagnostic platforms.

The cancer profiling market size is expected to see rapid growth in the next few years. It will grow to $25.62 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing demand for precision medicine approaches, expansion of companion diagnostics, growing use of liquid biopsy technologies, rising investments in oncology diagnostics, increasing integration of profiling in routine clinical workflows. Major trends in the forecast period include increasing adoption of ngs-based cancer profiling, rising use of comprehensive genomic panels, growing integration of ai in data interpretation, expansion of personalized oncology diagnostics, enhanced focus on early molecular detection.

The rising incidence of cancer is expected to drive the growth of the cancer profiling market in the coming years. Cancer incidence refers to the number of new cancer cases within a specific population over a defined period. The increase in cancer cases is attributed to urbanization, an aging population, changing lifestyles, and environmental and genetic factors. Cancer profiling helps identify specific molecular or genetic alterations in a tumor, such as gene mutations or other changes in tumor DNA, which play a crucial role in the cancer treatment process. For example, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, approximately 165,000 Australians were newly diagnosed with cancer, averaging over 450 cases per day, with males accounting for about 55% of these diagnoses. Hence, the growing incidence of cancer is fueling the expansion of the cancer profiling market.

Major companies in the cancer profiling market are concentrating on technological innovations such as simultaneous whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays to deliver more comprehensive, tissue-preserving, and clinically actionable molecular diagnostics for precision oncology. These assays integrate DNA (exome) and RNA (transcriptome) analysis in a single workflow, allowing detection of genomic variants (including SNVs, indels, and copy-number alterations) along with gene expression or fusion events, unlike conventional NGS tests that require separate assays or limited gene panels. For example, in November 2024, Caris Life Sciences, a US-based precision medicine company, received FDA approval for MI Cancer Seek, an NGS in vitro diagnostic that simultaneously performs WES and WTS. The assay utilizes total nucleic acid (TNA) from FFPE tumor tissue to identify single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications in breast cancer. By combining DNA and RNA profiling in a single test, it conserves tissue, provides clinically actionable companion diagnostic (CDx) indications across multiple tumor types, and speeds up therapy selection through a unified genomic framework.

In January 2023, Agilent Technologies, a US-based biotechnology research company, acquired Avida Biomed Inc. for an undisclosed amount. This acquisition is intended to strengthen Agilent's capabilities in molecular biology, particularly in developing advanced tools and technologies for synthetic biology applications. Avida Biomed Inc. is a US-based biotechnology research company.

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation.

North America was the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cancer profiling market by increasing costs of imported sequencing instruments, reagents, bioinformatics software, and laboratory consumables. Diagnostic laboratories in North America and Europe are most affected due to reliance on imported advanced technologies, while Asia-Pacific faces higher costs in test kit production. These tariffs are raising testing costs and impacting lab expansion plans. However, they are also encouraging local manufacturing of diagnostic kits, regional sequencing infrastructure development, and innovation in cost-efficient cancer profiling solutions.

The cancer profiling market research report is one of a series of new reports that provides cancer profiling market statistics, including cancer profiling industry global market size, regional shares, competitors with a cancer profiling market share, detailed cancer profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer profiling industry. This cancer profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer profiling is a diagnostic procedure performed to examine the genetic information of tumor cells in the body. It reveals information about specific molecular or genetic alterations in a tumor, such as gene mutations or other changes in tumor DNA.

The primary technologies used in cancer profiling include immunoassays, PCR (polymerase chain reaction), NGS (next-generation sequencing), microarrays, and in-situ hybridization. Immunoassays are laboratory tests that detect the concentration of specific proteins or other biomolecules in blood or urine samples. Genomic biomarkers and protein biomarkers are utilized for profiling various cancers, including breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others, for research, clinical use, screening, diagnostics, prognostics, and additional applications.

The cancer profiling market consists of revenues earned by entities by providing services such as surgery, chemotherapy, radiotherapy, hormonal therapy, and immunotherapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. Cancer profiling also includes sales of diagnostic tests and spectrometers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.